Research Summary

My cancer-related research centers around Kaposi sarcoma (KS) and its etiologic agent, Kaposi’s sarcoma-associated herpesvirus (KSHV), with work both in the US and in Africa.

My qualifications for research include both theoretical background and practical experience. I am Director of the UCSF Training in Clinical Research (TICR) Program, which provides graduate-level didactic training in clinical, epidemiologic, and translational research methods to graduate students, post-doctoral fellows, and junior faculty members at UCSF. The TICR Program, which is supported by the UCSF NIH-sponsored Clinical and Translational Science Award (CTSA), includes 33 different courses spanning “laboratory to human subjects” translational research, traditional clinical and epidemiologic research, and “evidence to practice” implementation science research. In direct teaching, I am the course director of “Epidemiologic Methods,” the program’s foundational course in research methods, and the “Master’s Program Seminar Series.” On a practical level, I have extensive experience in both observational and experimental research in both the US and Africa. In the US, I am Co-Director of the Population and Clinical Sciences Core of the UCSF NIH-sponsored Center for AIDS Research (CFAR), which manages the 1800-subject UCSF SCOPE cohort, a vehicle that has supported collaborative research leading to over 200 publications since 2000. In Africa, I am the Principal Investigator (PI) for U54 CA190153 (a project which focuses on the early detection and prevention of KS in Uganda); PI for the UCSF component of the East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium (U01 AI069911), in which I direct the working group on cancer; PI for the recently completed R01 CA119903 (a randomized trial for the therapy of KS in Africa); PI for the recently completed D43 CA153717 (a training grant related to KS in Uganda); and Director of the Data Coordinating Center for the 750-subject Mbarara-based Uganda AIDS Rural Treatment Outcomes (UARTO) Cohort. UARTO, which has spun off over 50 publications from collaborative projects since 2006, is a microscopic complement of IeDEA. In all of this work, I have had broad experience with study design, instrument development, study recruitment/ retention, data collection, quality enhancement, data reporting, biostatistical analysis, manuscript preparation, and financial management.

Research Funding

  • July 13, 2020 - June 30, 2025 - United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related Cancers, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: U54CA254571
  • August 10, 2019 - April 30, 2024 - Training in Clinical and Epidemiological Research for Liberia (TRACER), Principal Investigator. Sponsor: NIH/FIC, Sponsor Award ID: U2RTW011281
  • August 17, 2016 - July 31, 2022 - Early Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings using KS-Detect, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: UH3CA202723
  • September 24, 2001 - August 31, 2021 - Center for AIDS Prevention Studies, Co-Investigator. Sponsor: NIH/NIMH, Sponsor Award ID: P30MH062246

Education

Johns Hopkins University; Baltimore, Maryland, BA, 1979-83, Biology
University of Pennsylvania; Philadelphia, MD, 1983-88, Medicine
UC, San Francisco, 1988-89, Medicine - Internship
UC, San Francisco, 1989-91, Medicine - Residency 
UC, San Francisco, 1991-92, Medicine - Chief Residency
UC, Berkeley, MPH, 1992-93, Epidemiology
UC, San Francisco, 1993-97, Infectious Diseases - Fellowship
UC, San Francisco, 1993-97, AIDS Prevention - Fellowship

Honors & Awards

  • 1982
    Phi Beta Kappa
  • 1988
    Alpha Omega Alpha
  • 1988
    Merck Manual Award, University of Pennsylvania School of Medicine
  • 1989
    Diplomate, National Board of Medical Examiners
  • 1991
    Diplomate, American Board of Internal Medicine
  • 1996
    Diplomate, American Board of Internal Medicine, Subspecialty in Infectious Diseases
  • 1998
    New Investigator Award, UCSF Center for AIDS Research (CFAR)
  • 2009
    Stephen B. Hulley Award for Excellence in Instruction in Methods of Clinical Research at UCSF

Selected Publications

  1. Rutishauser RL, Deguit CDT, Hiatt J, Blaeschke F, Roth TL, Wang L, Raymond KA, Starke CE, Mudd JC, Chen W, Smullin CP, Matus-Nicodemos R, Hoh R, Krone MR, Hecht FM, Pilcher CD, Martin JN, Koup RA, Douek DC, Brenchley JM, Sékaly RP, Pillai SK, Marson A, Deeks SG, McCune JM, Hunt PW TCF-1 regulates HIV-specific CD8+ T cell expansion capacity.  View on PubMed
  2. VanderWeele TJ, Martin JN, Mathur MB E Values and Incidence Density Sampling.  View on PubMed
  3. McLaughlin MM, Ma Y, Scherzer R, Rahalkar S, Martin JN, Mills C, Milush J, Deeks SG, Hsue PY Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection.  View on PubMed
  4. Schnittman SR, Deitchman AN, Beck-Engeser G, Ahn H, York VA, Hartig H, Hecht FM, Martin JN, Deeks SG, Aweeka FT, Hunt PW Some But Not All Biomarkers of Immune Activation Remain Abnormal Despite Very Early Treatment of HIV.  View on PubMed
  5. Benitez AE, Musinguzi N, Bangsberg DR, Bwana MB, Muzoora C, Hunt PW, Martin JN, Haberer JE, Petersen ML Super learner analysis of real-time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non-differentiated care approaches for persons living with HIV in rural Uganda.  View on PubMed
  6. Peluso MJ, Bacchetti P, Ritter KD, Beg S, Lai J, Martin JN, Hunt PW, Henrich TJ, Siliciano JD, Siliciano RF, Laird GM, Deeks SG Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy.  View on PubMed
  7. Musinguzi N, Castillo-Mancilla J, Morrow M, Byakwaga H, Mawhinney S, Burdo TH, Boum Y, Muzoora C, Bwana BM, Siedner MJ, Martin JN, Hunt PW, Bangsberg DR, Haberer JE Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression.  View on PubMed
  8. Deguit CDT, Hough M, Hoh R, Krone M, Pilcher CD, Martin JN, Deeks SG, McCune JM, Hunt PW, Rutishauser RL Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection.  View on PubMed
  9. Kaida A, Kabakyenga J, Bwana M, Bajunirwe F, Muyindike W, Bennett K, Kembabazi A, Haberer JE, Boum Y, Martin JN, Hunt PW, Bangsberg DR, Matthews LT High Incidence of Intended Partner Pregnancy Among Men Living With HIV in Rural Uganda: Implications for Safer Conception Services.  View on PubMed
  10. Carrico AW, Hunt PW, Neilands TB, Dilworth SE, Martin JN, Deeks SG, Riley ED Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy.  View on PubMed
  11. Jarolimova J, Kabakyenga J, Bennett K, Muyindike W, Kembabazi A, Martin JN, Hunt PW, Boum Y, Haberer JE, Bangsberg DR, Kaida A, Matthews LT Contraceptive use following unintended pregnancy among Ugandan women living with HIV.  View on PubMed
  12. Bachtel ND, Umviligihozo G, Pickering S, Mota TM, Liang H, Del Prete GQ, Chatterjee P, Lee GQ, Thomas R, Brockman MA, Neil S, Carrington M, Bwana B, Bangsberg DR, Martin JN, Kallas EG, Donini CS, Cerqueira NB, O'Doherty UT, Hahn BH, Jones RB, Brumme ZL, Nixon DF, Apps R HLA-C downregulation by HIV-1 adapts to host HLA genotype.  View on PubMed
  13. Young CR, Kaida A, Kabakyenga J, Muyindike W, Musinguzi N, Martin JN, Hunt PW, Bangsberg DR, Haberer JE, Matthews LT Prevalence and correlates of physical and sexual intimate partner violence among women living with HIV in Uganda.  View on PubMed
  14. Muiru AN, Bibangambah P, Hemphill L, Sentongo R, Kim JH, Triant VA, Bangsberg DR, Tsai AC, Martin JN, Haberer JE, Boum Y, Plutzky J, Hunt PW, Okello S, Siedner MJ Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda.  View on PubMed
  15. Ayers LW, Barbachano-Guerrero A, McAllister SC, Ritchie JA, Asiago-Reddy E, Bartlett LC, Cesarman E, Wang D, Rochford R, Martin JN, King CA Mast Cell Activation and KSHV Infection in Kaposi Sarcoma.  View on PubMed
  16. Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.  View on PubMed
  17. McCluskey SM, Lee GQ, Kamelian K, Kembabazi A, Musinguzi N, Bwana MB, Muzoora C, Haberer JE, Hunt PW, Martin JN, Boum Y, Bangsberg DR, Harrigan PR, Siedner MJ Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.  View on PubMed
  18. Chang JL, Tsai AC, Musinguzi N, Haberer JE, Boum Y, Muzoora C, Bwana M, Martin JN, Hunt PW, Bangsberg DR, Siedner MJ Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.  View on PubMed
  19. Castillo-Mancilla JR, Morrow M, Boum Y, Byakwaga H, Haberer JE, Martin JN, Bangsberg D, Mawhinney S, Musinguzi N, Huang Y, Tracy RP, Burdo TH, Williams K, Muzzora C, Hunt PW, Siedner MJ Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression.  View on PubMed
  20. Wong C, Gange SJ, Moore RD, Justice AC, Buchacz K, Abraham AG, Rebeiro PF, Koethe JR, Martin JN, Horberg MA, Boyd CM, Kitahata MM, Crane HM, Gebo KA, Gill MJ, Silverberg MJ, Palella FJ, Patel P, Samji H, Thorne J, Rabkin CS, Mayor A, Althoff KN Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States.  View on PubMed

Go to UCSF Profiles, powered by CTSI